EOM Pharmaceuticals Holdings, Inc.
IMUCOTCHealthcare● Active
$0.27
+$0.06(+27.02%)
Market Cap$30571843
P/E Ratio—
52W High$0.34
52W Low$0.036
EOM Pharmaceuticals Holdings, Inc. (IMUC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMUC · earnings · updated Jun 10, 2026
Latest Earnings
Q3 FY2018Report Date: Aug 13, 2018EPS Actual
-$0.10
Revenue
—
Fiscal Period
Q3 FY2018
FY ends December
Report Date
Aug 13, 2018
After Market Close
IMUC reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q3 FY2018 | Aug 13, 2018 | — | -$0.10 | — | — | — | — |
| — Q2 FY2018 | May 14, 2018 | — | -$0.20 | — | — | — | — |
| — Q1 FY2018 | Mar 13, 2018 | — | -$0.10 | — | — | — | — |
| — Q4 FY2017 | Nov 21, 2017 | — | -$4.00 | — | — | — | — |
| — Q3 FY2017 | Aug 14, 2017 | — | -$10.20 | — | — | — | — |
| — Q2 FY2017 | May 15, 2017 | — | -$16.40 | — | — | — | — |
| ▼ Q1 FY2017 | Mar 9, 2017 | -$12.00 | -$13.60 | -13.3% | — | — | — |
| ▲ Q4 FY2016 | Nov 10, 2016 | -$20.00 | -$16.00 | +20.0% | — | — | — |
Q3 FY2018
Aug 13, 2018
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2018
May 14, 2018
EPS Actual
-$0.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2018
Mar 13, 2018
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2017
Nov 21, 2017
EPS Actual
-$4.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2017
Aug 14, 2017
EPS Actual
-$10.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2017
May 15, 2017
EPS Actual
-$16.40
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2017
Mar 9, 2017Miss
EPS Actual
-$13.60
EPS Est.
-$12.00
EPS Surpr.
-13.3%
Revenue
—
Q4 FY2016
Nov 10, 2016Beat
EPS Actual
-$16.00
EPS Est.
-$20.00
EPS Surpr.
+20.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2018 | Aug 13, 2018 | — | No price data | — | — |
| — Q2 FY2018 | May 14, 2018 | — | No price data | — | — |
| — Q1 FY2018 | Mar 13, 2018 | — | No price data | — | — |
| — Q4 FY2017 | Nov 21, 2017 | — | No price data | — | — |
| — Q3 FY2017 | Aug 14, 2017 | — | No price data | — | — |
| — Q2 FY2017 | May 15, 2017 | — | No price data | — | — |
| ▼ Q1 FY2017 | Mar 9, 2017 | -13.3% | No price data | — | — |
| ▲ Q4 FY2016 | Nov 10, 2016 | +20.0% | No price data | — | — |
Q3 FY2018—
Report Date
Aug 13, 2018
EPS Beat/Miss
—
Price Before
—
Price After
—
Q2 FY2018—
Report Date
May 14, 2018
EPS Beat/Miss
—
Price Before
—
Price After
—
Q1 FY2018—
Report Date
Mar 13, 2018
EPS Beat/Miss
—
Price Before
—
Price After
—
Q4 FY2017—
Report Date
Nov 21, 2017
EPS Beat/Miss
—
Price Before
—
Price After
—
Q3 FY2017—
Report Date
Aug 14, 2017
EPS Beat/Miss
—
Price Before
—
Price After
—
Q2 FY2017—
Report Date
May 15, 2017
EPS Beat/Miss
—
Price Before
—
Price After
—
Q1 FY2017—
Report Date
Mar 9, 2017
EPS Beat/Miss
-13.3%
Price Before
—
Price After
—
Q4 FY2016—
Report Date
Nov 10, 2016
EPS Beat/Miss
+20.0%
Price Before
—
Price After
—
Beat Rate1 / 8 quarters
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMUC ends December
EOM Pharmaceuticals Holdings, Inc. (IMUC) most recently reported earnings on August 13, 2018 for Q3 FY2018, posting EPS of $-0.10 (in line with the analyst consensus of —).
Each quarter, investors track IMUC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMUC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMUC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMUC earnings · 3 questionsEOM Pharmaceuticals Holdings, Inc.'s next earnings report is expected around TBD. IMUC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMUC historically reports after market close (AMC).
IMUC earnings datewhen is IMUC earningsIMUC next earnings datewhen does IMUC report earningsIMUC earnings calendar
▸ Source: FMP · EOM Pharmaceuticals Holdings, Inc. SEC filings · US GAAP · EOM Pharmaceuticals Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026